News and Reports
-
SWIXX AND ALBIREO INK PAN-CEE AGREEMENT FOR BYLVAY®
4 November 2021Download -
IO Biotech, Inc. Announces Pricing of Initial Public Offering
4 November 2021Download -
Pyxis Announces Pricing of Upsized Initial Public Offering
8 October 2021Download -
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
14 September 2021Download -
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
24 June 2021Download -
Ambrx Announces Pricing of Initial Public Offering
18 June 2021Download -
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
20 May 2021Download -
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
4 May 2021Download -
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
30 April 2021Download -
Mineralys Therapeutics Closes $40 Million Series A Funding
6 April 2021Download -
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
30 March 2021Download -
IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)
22 March 2021Download -
SWIXX SIGNS CEE REGIONAL AGREEMENT WITH JAZZ PHARMACEUTICALS FOR VYXEOS® LIPOSOMAL
15 March 2021Download -
Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals
15 March 2021Download -
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
12 March 2021Download -
Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
12 March 2021Download -
NEURELIS ANNOUNCES CLOSE OF $114 MILLION SERIES D FINANCING ROUND TO ADVANCE NEUROSCIENCE FOCUS
10 March 2021Download -
eGenesis Announces $125 Million Series C Financing
2 March 2021Download -
SWIXX SIGNS CEE REGIONAL AGREEMENT WITH SEAGEN FOR TUKYSA®
1 March 2021Download -
NovellusDx Establishes Fore Biotherapeutics and Appoints Dieter Weinand as Chairman of the Board and Usama Malik as Chief Executive Officer and Director of the Board
22 February 2021Download -
Swixx BioPharma SA of Baar, Switzerland announced today that it had signed eighteen deals for new territories and / or products over the past year
5 February 2021Download -
Horizon Therapeutics to acquire HBM portfolio company Viela Bio for USD 3.05 billion in cash
1 February 2021Download -
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis
1 February 2021Download -
Narrow River Management Announces Formation and Financing of Two New Companies Developing Therapies for Renal Diseases
27 January 2021Download -
Farmalatam Holding Inc. (Farmalisto) achieves investment of US $ 18 million from the IDB Invest, HBM Healthcare Investments Ltd. and Morgan Río Capital Management
15 January 2021Download